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Abstract
Background: Medulloblastoma (MB) is the most common malignant childhood brain tumor with the propensity to
disseminate at an early stage, and is associated with high morbidity. New treatment strategies are needed to
improve cure rates and to reduce life-long cognitive and functional deficits associated with current therapies.
Extracellular Vesicles (EVs) are important players in cell-to-cell communication in health and diseases. A clearer
understanding of cell-to-cell communication in tumors can be achieved by studying EV secretion in
medullospheres. This can reveal subtle modifications induced by the passage from adherent to non-adherent
growth, as spheres may account for the adaptation of tumor cells to the mutated environment.
Methods: Formation of medullospheres from MB cell lines stabilized in adherent conditions was obtained through
culture conditioning based on low attachment flasks and specialized medium. EVs collected by ultracentrifugation,
in adherent conditions and as spheres, were subjected to electron microscopy, NanoSight measurements and
proteomics.
Results: Interestingly, iron carrier proteins were only found in EVs shed by CSC-enriched tumor cell population of
spheres. We used iron chelators when culturing MB cell lines as spheres. Iron chelators induced a decrease in
number/size of spheres and in stem cell populations able to initiate in vitro spheres formation.
Conclusions: This work suggests a not yet identified role of iron metabolism in MB progression and invasion and
opens the possibility to use chelators as adjuvants in anti-tumoral chemotherapy.
Background
Medulloblastoma (MB) is the most common malignant
childhood brain tumor with a propensity to disseminate at
an early stage [1]. Although multimodal treatments have
improved survival rates for patients with MB [2], these
tumors are associated with high morbidity [3]. In addition
to the histological classification, an international consensus
paper endorsed and refined a molecular classification into
four groups based on meta-analysis of expression profiling
[4]. This new stratification tool has not yet produced any
clinical results in terms of new treatment strategies or
improving the quality of life of survivors. The current
standard of care for patients with MB involves surgery
followed by craniospinal irradiation and chemotherapy. In
infants and young children, radiation therapy is rarely used
because of the risk of long-term neurocognitive deficits.
Therefore, new treatment strategies are urgently needed
to improve cure rates, to decrease neurotoxicity, and to
reduce life-long cognitive and functional deficits associ-
ated with current therapies.
Recently, a role for Cancer Stem Cells (CSC) (also
referred to as brain tumor-initiating cells) [5] in MB
was proposed, which is a tumor with relevant molecular
heterogeneity. We have previously described medullo-
spheres (MBS) [6], obtained with a serum-free medium
(enabling the formation and growth of spheres), in order
to study CSC in vitro.
Furthermore, over the past decade, a new mode of
intercellular communication has been described, namely
the release of membrane vesicles known as Extracellular
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Vesicles (EVs)/Microvesicles/Exosomes [7]. EVs have been
implicated in several physiological and pathophysiological
processes, including tumor growth and progression [8].
There has been only one study reporting the role of EVs
in MB [9], but relevant signaling molecules activated in
MB have been studied in tumors of different histotypes
[10–12]. Therefore, the study of EVs from MB cell lines
enriched in Cancer Stem Cells is a promising approach
aimed at gaining a greater insight into tumor cell adaptive
modifications to the microenvironment, both in vitro and
in vivo, and at finding new diagnostic tools and treatment
strategies [9].
In the present study we identified, through a proteomic
approach [13, 14], a set of proteins carried by EVs originat-
ing from MB cell lines cultured both in standard conditions
of adhesion (MB) and as spheres (MBS). Interestingly, iron
carrier proteins were only identified in EVs shed by CSC-
enriched tumor cell populations. Iron depletion causes cell
arrest between G1/S phases and leads to inhibition of cell
proliferation and apoptosis suggesting that the use of iron
chelators could be a novel approach in cancer treatment
[15]. In fact, although iron chelation has been shown to
protect against disease progression and/or limit iron accu-
mulation in some rare neurological disorders and hemoglo-
binopathies [16], the role of iron in the progression of MB
remains poorly understood. The use of iron chelators in
our MBS culture resulted in a decrease in the number/size
of spheres and caused a decrease in stem cell populations
able to initiate the formation of in vitro spheres. In conclu-
sion, this work clearly implicates iron metabolism in MB
progression and invasion.
Methods
Cell culture, reagents and antibodies
DAOY cell line was purchased from ATCC (U.K.),
UW228 and ONS-76 cell lines were kindly provided by
Dr. Charles G. Eberhart (John Hopkins University,
Baltimore, MD) with the agreement of Dr. Mike Bobola
(University of Washington, Seattle, WA). MB cell lines
DAOY, UW228 and ONS-76 were cultured at 37 °C, in
5 % CO2 as previously described [6]. Briefly, DAOY was
cultured in MEM/EBSS supplemented with 10 % FBS,
UW228 in DMEM/F12 10 % FBS and ONS-76 in RPMI
supplemented with 10 % FBS.
Iron chelators: deferoxamine (DFO), 2-pyridylketone
4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and Iron
introduced through Ferric ammonium citrate (FAC) in
cellular culture were purchased from Sigma-Aldrich
(Milan, Italy). DFO, Dp44mT, and FAC were used at
concentrations ranging from 5 to 100 μM, 0.1 to 5 μM,
and 50 to 200 μM, respectively.
The stemness profile of the MBS were characterized
by immunofluorescence staining: MBS were previously
grown in low adherent conditions in order to allow
sphere formation, and spheres were then stained with anti-
bodies against β catenin (Cell Signaling Technology, Inc.,
Danvers, MA, USA) and SOX-2, FITC or PE secondary
antibodies were purchased from Abcam (Cambridge, UK).
Tumor sphere generation assay
In order to produce medullospheres (MBS) from DAOY,
UW228 and ONS-76, cells were grown at confluence in
adherent conditions, trypsinized, pelleted and plated
(6 × 104/ml) in ultra-low attachment T25 Flasks (Corn-
ing Inc., NY, USA) for a further 7 days in serum-free
EUROMED CSC (EUROCLONE Spa, Pero, MI, Italy)
medium. Culture conditioning based on low attachment
flasks, specialized medium and formation of spheres en-
abled the expansion of the CSC population. Suspensions
of spheres from all cell lines were collected and counted in
96-well plates by inverted microscopy (Olympus CKX41).
Clonal sphere formation assay
Colony-forming efficiency and self-renewal ability were
tested by limiting dilution.
DAOY, UW228 and ONS-76 adherent cells were grown
and dissociated as described above and a single cell per well
was plated in 150 μl of growth medium in a low adhesion
96-well culture plate. A volume of 25 μl of medium per
well was added every 5 days. The number of clonal tumor
spheres for each 96-well culture plate was evaluated after
14 days of culture.
Isolation and analysis of EVs
EVs were obtained both from supernatants of MB adherent
cell lines and from MBS cultured overnight in FBS-devoid
medium. To obtain EVs, after centrifugation at 10,000 g
for 20 min to remove debris, cell-free supernatants were
centrifuged at 100,000 g (Beckman Coulter Optima L-90 K
ultracentrifuge) for 1 h at 4 °C, washed in PBS and sub-
jected to a second ultracentrifugation under the same con-
ditions. EV pellets were then resuspended in 50 μL PBS or
in RIPA lysis buffer. The protein content of EVs was quan-
tified by the Bradford method (BioRad, Hercules, CA,
USA). The presence and purity of EVs were verified by
western blot analysis using antibodies against HSP70 and
HSP90 from Abcam (Cambridge, UK), and CD63 pur-
chased from Santa Cruz Biotechnology, Inc (Dallas, Texas,
USA), which are specific markers of EVs . Moreover, ana-
lysis of the size distribution of EVs was performed using
NanoSight NS300 with a 488 blue laser (NanoSight Ltd,
Minton Park UK). Through the laser light source the par-
ticles in the sample are illuminated and the scattered light
is captured by the camera and displayed on the connected
computer running Nanoparticle Tracking Analysis (NTA).
Using NTA, the particles are automatically tracked and
sized based on Brownian motion and the diffusion
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coefficient (Dt). Results are displayed as a frequency size
distribution graph and output to a spreadsheet.
Transmission electron microscopy
EVs isolated after 100,000 g ultracentrifugation were resus-
pended in 50 μl PBS and a drop of 8 μl of resulting suspen-
sion was adhered to a Cu-Rh formvar-coated 200 mesh
grid for 2 min. Absorbing paper was gently used to remove
any excess of the suspension, by holding it close to the side
of the grid, without making contact with the coated area.
EVs were immediately fixed with 2.5 % glutaraldehyde in
PBS for 1 min and rinsed with several drops of distilled
water on the grid. EVs were then positively stained with
1 % uranyl acetate for 1 min. Subsequent observations were
carried out by a ZEISS EM 109 Transmission Electron
Microscope at 80 kV.
Proteomic analysis
EVs from adherent DAOY, UW228 and ONS-76 cells
and spheres were separated by SDS-PAGE on 4to 20 %
Tris-Glycine Gels (Thermo Scientific) in triplicate; entire
lanes of 1-DE gels were then cut out for mass spectrom-
etry analysis.
MS analysis and database searches were performed
as previously described [17]. Briefly, gel slices from
Coomassie-stained gels were excised, and protein digestion
was carried out with trypsin. MS analysis of peptides was
performed using a MALDI-TOF spectrometer (MALDI
micro MX; Waters, Milford, MA, USA) operating on
reflectron mode. Samples were loaded onto the MALDI
target using 1.5 μl of the tryptic digest mixed in a 1:1 ratio
with a solution of α-cyanohydroxycinnamic acid (10 mg/
ml) in 40 % v⁄v acetonitrile, 60 % v⁄v trifluoroacetic acid
0.1 %. Peak lists were generated by ProteinLynx (Waters,
Milford, MA, USA) and data preparation was carried out
using the following parameters: external calibration with
lock mass using a mass of 2465.1989 Da for ACTH (adre-
nocorticotropic hormone), background subtract type adap-
tive combining all scans, and de-isotoping with a threshold
of 1 %. The 25 most intense masses were used for database
searches against the SWISSPROT database using the free
search program MASCOT (http://www.matrixscience.com);
the search settings allowed one missed cleavage with the
trypsin enzyme selected, oxidation of methionine as a poten-
tial variable modification, a peptide tolerance of 100 ppm,
taxon human. Hemopexin used in western blot analysis was
a gift from E. Tolosano [18].
Western blotting
Protein samples were extracted by RIPA (1 M Tris, 5 M
NaCl, 1 % Triton, 1 % Na-deoxycolate, 1 % SDS) and sepa-
rated on 4 to 20 % Tris-Glycine Gels. Western-blot ana-
lysis of adherent cells, MBS and EVs was performed as
previously described [19], using the following antibodies
against CD63, HSP90, HSP70, and Actin. Actin was pur-
chased from Santa Cruz Biotechnology, and HPR mouse
secondary antibodies from Cell Signaling Technology, Inc
(Danvers, MA, USA).
Statistical analysis
The results are representative of at least three independ-
ent experiments performed in triplicate and are expressed
as the means ± SEM. Statistical analysis of the data was
performed using the Student’s t test.
Protein network
Proteins experimentally identified in both adherent cells
and spheres were evaluated by means of a web platform
tool known as ProteinQuest (PQ, BioDigitalValley srl,
Pont-Saint-Martin, AO, Italy). PQ automatically retrieved
all relevant biological information from PubMed abstracts
and captions from free full text articles, US patents and
Clinical Trials.
The image captions were extracted using the BFO Java
library (http://bfo.com/) on the PDF version of the scientific
papers [20].
The PQ database contains documents already tagged
with biomedical dictionaries and ontologies such as
proteins, drugs, cells, miRNAs, diseases, bioprocesses,
clinical and biological techniques, etc. Each assign-
ment of terms takes into account all the corresponding
aliases, for disambiguation.
The biological relationships between identified terms
and their translation into a relevant result can be explored
by analyzing the co-occurrences for pairs of terms. The
web application automatically generates graphs. In this
study, the protein networks were generated by selecting
the proteins that are differentially expressed in the experi-
ments described above, already associated in the same
papers (abstracts or captions). Networks connecting all of
these proteins from the literature were visualized using
Cytoscape [21], a popular software platform for network
analysis, and further characterized by Bingo plugins [22]
for Gene Ontology Analysis.
Results
Isolation of EVs and morphological characterization
Different medulloblastoma cell lines of (DAOY, UW228
and ONS-76) were cultured both in adherent conditions
(MB) and as spheres (MBS) (Fig. 1a). As previously de-
scribed [6], culture conditions of MB in low adhesion
allowed formation of spheres enriched with CSC. To verify
the stemness profile of MBS, immunofluorescence staining
was performed using antibodies against β catenin and Sox2,
specific markers closely linked to neuronal CSC. As shown
in Fig. 1b, β catenin and Sox-2 were highly expressed in
MBS compare to MB adherent cell lines. EVs from DAOY,
UW228 and ONS-76 MB cell lines and MBS were then
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harvested by ultracentrifugation and characterized by
ultrastructural morphology using electron microscopy
(TEM) (Fig. 1c), NanoSight analysis (Fig. 1d) and west-
ern blotting (Fig. 1e). TEM analysis showed that the
diameter of vesicles isolated through ultracentrifuga-
tion procedures ranged approximately from 50 to
120 nm and that these vesicles were surrounded by a
lipid layer with a cup-shaped morphology. The vesicle
surface appeared slightly wrinkled and they were
present in both isolated and aggregated forms in the
two culture conditions (adhesion and spheres). More-
over, smaller vesicles (<50 nm) not displaying the cup-
shaped morphology, were sometimes observed and
such vesicles were not considered as being exosomes.
Finally, fragments of apoptotic cells, larger than exo-
somes, were occasionally observed. In conclusion, the
Fig. 1 Purification of microvescicles from medulloblastoma cell lines and medulloblastoma spheres. a MB cell lines DAOY, UW228 and ONS-76
were cultured both in adhesion (MB) and as spheres (MBS). MBS were plated in ultra-low attachment flasks in EUROMED CSC serum-free
medium (Euroclone code: ECM0894D). 4X magnification. b Representative image of immunofluorescence staining at 63X magnification of MB
and MBS: (a, d) negative control, (b,e) β catenin (red), (c,f) Sox2 (red). c Electron microscopy representative images of exosomes from Medulloblastoma
(MB) and Medulloblastoma spheres (MBS) from DAOY cells purified by ultracentrifugation. Note the cup-shaped morphology of vesicles (a). An aggregate
of three exosomes (arrow) is clearly evident compared with smaller non cup-shaped vesicles in the background (b). d Nanoparticle tracking analysis (NTA)
of MB and MBS EVs using the NanoSight instrument. Plot shows EV particle size distribution profiles and concentration measurements. The NanoSight
instrument is based on a conventional optical microscope and uses a laser light source to illuminate nano-scale particles. e Western blot analysis of EV
extracts from MB (adhesion), MBS (spheres) and of cells originating from EVs. Antibodies against HSP90, Actin and CD63 were used. CD63 is a specific
marker of microvesicles (MVs). Actin was used as a loading control
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great majority of EVs isolated through ultracentrifuga-
tion procedures were present as exosomes.
EVs were then analyzed by means of nanoparticle
tracking analysis (NTA) using the NanoSight instrument
(Fig. 1d) in order to visualize the size distribution of
EVs. As shown in Fig. 1d, NanoSight analysis indicated
that purified EVs had a diameter comprised between 50
to 120 nm and that the majority of particles displayed a
105 nm diameter, confirming the presence of exosomes.
Finally, western blot analysis also confirmed the pres-
ence of EVs in exosome-form in the pellet obtained by
the ultracentrifugation procedure, demonstrated by the
positivity of the EV lysate for CD63 and HSP90, which
are specific markers of exosomes (Fig. 1e).
Identification of proteins carried by EVs
To identify proteins carried by EVs, we performed three
independent purification experiments of EVs derived from
DAOY, UW228 and ONS-76, cultured both in adherent
conditions (MB) and as spheres (MBS). The 1-DE pattern
obtained after Coomassie staining of EV lysates revealed
striking differences in the proteomic profiles of EVs from
adherent cells (MB) vs. spheres (MBS), as indicated by the
arrows (Fig. 2a). These differences were found in all the
three cell lines of MBS EVs. The 74 most intense bands in
the gels were cut and analyzed by mass spectrometry.
Mass spectrometry analysis by MALDI-TOF identified 74
proteins: of these, 33 were unique proteins and the others
were isoforms of the same protein. These 33 proteins
identified (Table 1) were then analyzed using the Protein-
Quest software in order to obtain a representative network
in which EV proteins experimentally identified (nodes) in
adherent cells (light green) and spheres (green) or in both
(magenta) were linked together (edges) on the basis of the
data from the literature (Fig. 2b). Indeed, the node size
was proportional to the number of papers in which the
proteins had been studied, while the edge width was pro-
portional to the document number in which the two pro-
teins were described together. The secretome of MB from
adherent cells and spheres carries Annexin 2, Annexin 5,
proteins with calcium channel activity and a potential role
in cellular signal transduction, inflammation, growth and
differentiation, galectin-3-binding proteins and 78 kDa
glucose-regulated proteins, which play different roles such
as monitoring protein transport through the cell.
The gene ontology analysis of the EV protein network
(Table 2) also highlighted a key role of other proteins
through their bioprocesses, such as positive regulation
of the nitric oxide biosynthetic process (p = 10−5),
chaperone-mediated protein complex assembly (p = 10−5),
heme metabolic process (p = 10−5), negative regulation of
apoptosis (p = 10−3), iron ion homeostasis (p = 10−3) and
positive regulation of angiogenesis (p = 10−3) involved in
MB cell-to-cell communications.
To further understand the role of these proteins, the
molecular functions were also evaluated. In this way, the
role of how these proteins exert cell-to-cell communica-
tions was defined: chaperone binding (p = 10−5), nitric-
oxide synthase regulator activity (p = 10−5), cell surface
binding (p = 10−5), and phospholipase inhibitor activity
(p = 10−4) (Table 2).
Interestingly, iron carrier proteins (Hemopexin and
Serotransferrin) were only identified in EVs shed by the
CSC-enriched tumor cell population of all three MB cell
lines analyzed. Therefore, to verify the robustness of the
proteomic identifications, western blotting analysis was
performed on EVs purified from MB and MBS. We con-
firmed that Hemopexin was highly expressed in DAOY,
UW228, and ONS76 EVs originating from medullospheres
compared to EVs coming from MB (Fig. 2c). Hemopexin
was also expressed in MB cells and MBS which gave rise
to EVs but at a very low level (data not shown), indicating
a clear enrichment in the Hemopexin iron carrier protein
in EVs from CSC. Therefore, on the basis of the proteomic
results obtained in the EVs shed by MBS, we decided to
investigate the influence of iron chelators on the forma-
tion of MB spheres.
Role of iron in cancer progression
We used two distinct classes of iron chelators. The first
was deferoxamine (DFO), a well-known iron chelator,
widely used clinically for the treatment of iron overload
in hemoglobinopathies, but impermeable to the cellular
membrane. The second iron chelator was Dp44mT, a new
compound able to pass through the cellular membrane.
As a positive control we also added iron in the form of
ferric ammonium citrate (FAC) to the culture medium of
the spheres.
Results obtained on UW228 MB cell lines revealed
that using a concentration of 1 μM of the Dp44mT iron
chelator on MBS cultures induced a 3-fold decrease in
the number of spheres and a 2-fold decrease in sphere
size compared to control spheres (Fig. 3a, b, c). DFO,
which is not permeable to cellular membranes did not
have any effect on the spheres. Moreover, adding iron to
the cell culture, by means of 50 μM FAC, induced a 2-fold
increase in the number and a 1.3-fold increase in the size of
spheres compared to controls (Fig. 3a, b, c). Finally, MB cell
lines were cloned by limiting dilution of dissociated cells by
plating one single cell per well into 96 well-culture plates in
the presence of 100 μM DFO, 1 μM Dp44mT or 50 μM
FAC. Dp44mT induced a 3-fold decrease in the number of
spheres formed by single cells and, conversely, the presence
of iron (in the form of FAC), resulted in a 3-fold increase in
the number of spheres compared to control cells (Fig. 3d).
These data indicate that a population of sphere-generating
cells with self-renewal ability is enriched in culture medium
containing iron, and that iron chelation seems to be able to
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decrease this self-renewal ability. Similar experiments were
performed on the DAOY cell line using fixed concentra-
tions of iron chelators and FAC and adding Dp44mT and
FAC to the medium for sphere culture (Fig. 4a). In DAOY
MBS formations, the presence of Dp44mT induced a 2-fold
decrease in the number of spheres formed compared to
controls. Conversely, the presence of iron in the culture
medium increased the number of spheres by 2-fold. The
co-presence of Dp44mT and FAC restored the number of
spheres to control levels. Again, the DFO chelator did not
Fig. 2 Proteomic analysis of EVs from MB, MBS and gene ontology analysis. a EVs from DAOY, UW228 and ONS-76 MB (adhesion culture) and MBS
(spheres) were separated on SDS-PAGE. Coomassie-G bands were excised from the gels and destained. In-gel enzymatic digestions were performed
before mass spectrometry analysis. b Representative network of the proteins (nodes) experimentally identified in adherent cells (purple), spheres
(green) or both (magenta) and already described together in at least one paper (edges). The node size is proportional to the number of papers in
which the proteins have been studied, while the edge width is proportional to the document number in which two proteins have been described
together (data obtained by means of ProteinQuest). c Western blot analysis of EVs extracted from MB (adhesion), MBS (spheres) of DAOY, UW228 and
ONS76 cells. Antibodies against Hemopexin were used. Actin was used as a loading control
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show any effect on sphere formation (Fig. 4b). Dp44mTalso
induced a decrease in sphere size (Fig. 4c) and in stemness
ability (Fig. 4d), and the presence of iron was shown to
favor the increase of the area of the spheres (Fig. 4c) and of
the stemness capacity (Fig. 4d). Finally, the co-presence of
Dp44mTand FAC decreased the area of the spheres to that
observed with the use of Dp44mT alone (Fig. 4c), but re-
stored the population of sphere-generating cells to control
levels (Fig. 4d). These data indicate that iron depletion
and/or the presence of iron can modulate the tumorigenic
properties of MB cells in vitro, affecting stem cell popula-
tions and cell-renewal abilities.
Discussion
A great deal of interest has been focused on exosomes
and microvescicles from mesenchymal stem cells [23]
and tumor cells as important means of intercellular
communication [24]. Depending on the type of cells of
origin and microenvironment investigated, EVs have
been demonstrated to influence several different aspects of
Table 1 Maldi-Tof proteomic identification
Abb. Acc. N° Full name PM p.l M.pep C %
shared_all ACTG_HUMAN P63261 ACTG1 Actin, cytoplasmic 2 41766 5,31 11 30
shared_all GRP78_HUMAN P11021 HSPA5 78 kDa glucose-regulated protein 72288 5,07 10 20
shared_all ACTB HUMAN Q96HG5 ACTB Actin, cytoplasmic 1 41710 5,29 11 30
shared_all ANXA2_HUMAN P07355 ANXA2 Annexin A2 38580 7,57 13 29
shared_all ANXA5_HUMAN P08758 ANXA5 Annexin A5 35914 4,94 8 33
shared_all TBCE_HUMAN Q15813 TBCE Tubulin-specific chaperone E 59309 6,32 7 16
shared_all FINC_HUMAN Q8IVI8 FN1 Fibronectin 262460 5,46 23 16
shared_all LG3BP_HUMAN Q08380 LGALS3BP Galectin-3-binding protein 65289 5,13 11 23
shared_sph HPX_HUMAN P02790 HPX Hemopexin 51643 6,55 10 26
shared_sph TRFE_HUMAN P02787 TF Serotransferrin 77014 6,81 11 17
adh CH60 HUMAN P10809 HSPD1 60 kDa heat shock protein, mitochondrial 61016 5,2 7 20
adh INHBA_HUMAN P08476 INHBA Inhibin beta A chain 47412 8,3 6 15
adh STIM1_HUMAN Q13586 STIM1 Stromal interaction molecule 1 77375 6,19 7 16
adh FRMD6_HUMAN Q96NE9 FRMD6 FERM domain-containing protein 6 71998 7,12 6 17
adh SIR6_HUMAN Q9NRC7 SIRT6 NAD-dependent protein deacetylase sirtuin-6 39094 9,31 6 19
adh EDIL3_HUMAN O43854 EDIL3 EGF-like repeat and discoidin I-like domain-containing protein 3 53730 7,08 8 20
adh ANGL2_HUMAN Q9UKU9 ANGPTL2 Angiopoietin-related protein 2 57068 7,23 7 19
adh HBB_HUMAN Q549N7 HBB Hemoglobin subunit beta 15988 6,75 6 53
adh HS90B HUMAN P08238 HSP90AB1 Heat shock protein HSP 90-beta 83212 4,97 9 17
adh G3P_HUMAN P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 36030 8,57 6 27
adh ZN552_HUMAN Q9H707 ZNF552 Zinc finger protein 552 46168 8,84 7 20
adh KI16B_HUMAN, Q8IYU0 KIF16B Kinesin-like protein KIF16B 151918 5,86 12 10
adh TINAL_HUMAN Q9GZM7 TINAGL1 Tubulointerstitial nephritis antigen-like 52353 6,54 7 16
adh SPF45_HUMAN Q96I25 RBM17 Splicing factor 45 45162 5,76 6 17
adh TPD53_HUMAN Q5TDQ0 TPD52L1 Tumor protein D53 22435 5,46 5 19
sph HS90A_HUMAN P07900 HSP90AA1 Heat shock protein HSP 90-alpha 84607 4,94 8 15
sph H4 UMAN P62805 HIST1H4A Histone H4 11360 11,36 5 51
sph CHCH5 HUMAN Q9BSY4 CHCHD5 Coiled-coil-helix-coiled-coil-helix domain-containing protein 5 12387 6,28 4 41
sph SYNE1_HUMAN Q9UJ06 SYNE1 Nesprin-1 1010456 5,37 18 3
sph ACTBM_HUMAN Q9BYX7 POTEKP Putative beta-actin-like protein 3 41989 5,91 6 25
sph TCPQ_HUMAN P50990 CCT8 T-complex protein 1 subunit theta 59583 5.42 8 20
sph ARI5B_HUMAN Q9H786 ARID5B AT-rich interactive domain-containing protein 5B 132292 8,89 8 10
sph BACD2_HUMAN Q13829 TNFAIP1 BTB/POZ domain-containing adapter for CUL3-mediated RhoA
degradation protein 2
36181 8,26 6 28
33 proteins identified by Maldi-Tof and classified as follows: proteins present in EVs both from MB and MBS (shared-all), proteins expressed in all EVs from MBS
(shared-sph) or only in adherent (adh) or spheres (sph) EVs
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regulation, ranging from inflammation and repair to im-
munity, invasion and metastasis. To date, no completely
unique protein marker for exosomes has been identified in
order to verify that the sample of EVs contained purified
exosomes and no cellular debris. As a result, a combination
of methods was required to characterize the EVs, including
determination of size and morphology of the EVs by elec-
tron microscopy, NanoSight analysis and western blotting
[23–26]. In addition, the purity of the sample can be deter-
mined by electron microscopy, and this method can pro-
vide an overview of the level of contamination of the
sample; for example, with larger vesicles, such as micropar-
ticles, apoptotic bodies or cell debris could be present in
the cell cultures, indicating poor condition. When isolating
EVs by ultracentrifugation, smaller vesicles (<50 nm), not
displaying the cup-shaped morphology, can sometimes be
present which significance is to be deepened. NanoSight
analysis gave indications of EV size distribution and con-
centrations. NanoSight could indicate the diameter dimen-
sion of the majority of EVs (predominant peak proportional
to concentration) and could also indicate the presence or
absence of aggregates (peaks exceeding 200 nm). Finally, it
was useful to perform a molecular analysis of protein
markers known to be expressed by exosomes through
western blotting analysis, showing the presence of specific
markers such as CD63 and HSP90. The combination of
these three analytic methods can demonstrate the pres-
ence of exosomes in the purified preparation of EVs.
The increasing interest in exosomes and microvesicles
in organic fluids and exhausted culture media of different
cell lines has opened new scenarios, and the role of EVs as
intercellular messengers has been widely investigated in
different physiological and pathological states. In parallel,
great efforts have been directed towards finding new
methods for early diagnosis of malignant tumors of
infancy and childhood, as well as to find innovative and
more effective therapeutic tools and strategies. EVs may
also reflect metabolic conditions of tumor cells in culture
and in Cancer Stem Cells. EVs shed by tumors have been
investigated as important factors as they act on the tumor
microenvironment and have been designated TEX (Tumor-
associated Exosomes) recognizing their role in the modifi-
cation of tumor-associated stroma from an inflammatory
phenotype towards a reparative one [27]. The most specific
bioprocesses characterized in EV proteins revealed that, in
MB tumors, EV communication sustains stemness, survival
and proliferation. As culture in suspension, or rather
spheres, in our case “medullospheres”, induced an enrich-
ment of Cancer Stem Cells, the modification of the
protein repertoire found in EVs purified from medullo-
spheres could most likely reflect an increased stemness
compared to the same cells grown in adherence. The
presence of medulloblastoma exosomes from cell lines
D283MED, DAOY, and UW228, has been previously
described [9].
Comparing our proteomic analysis with previous prote-
omic works on medulloblastoma [9] and brain tumor [28]
exosomes, many proteins are shared, as expected: ACTB,
G3P, GRP78, ANXA2, TRFE, CH60, HBB, HSP90. Other
identified proteins are not exactly the same, but belong to
the same functional class: TBCE (tubulin polymerization-
promoting protein family member 2), ZN552 (other zinc
finger proteins), KI16B (kinesin family member 16B), H4
(other histone proteins), CH60. The presence of proteins
related to iron metabolism, namely Hemopexin, a Heme-
binding protein with cytoprotective activity from free heme
toxicity, and serum transferrin was an unexpected finding
limited to EVs from medullospheres [15]. These proteins
are iron carrier proteins, suggesting a possible implication
of iron and heme metabolic processes, namely iron ion
Table 2 Gene ontology analysis of the EVs protein network
GO-ID P-VALUE Description of bioprocess Proteins
45429 1.86E-05 positive regulation of nitric oxide biosynthetic process HSP90AB1|HSP90AA1|HBB
20027 8.87E-05 heme metabolic process IN H BA|HPX
51131 8.87E-05 chaperone-mediated protein complex assembly HSP90AA1|HSPD1
43066 1.01E-03 negative regulation of apoptosis TF| HSPD11 HSPA51ANXA51ANGPTL2
55072 2.56E-03 iron ion homeostasis TF| HPX
45766 3.64E-03 positive regulation of angiogenesis TF|ANGPTL2
GO-ID P-VALUE Description of molecular functions Proteins
51082 3.30E-06 unfolded protein binding HSP90AB1|HSP90AA1|CCT8|HSPD1|HSPA5
51087 3.16E-05 chaperone binding TBCE|HSPD1|HSPA5
30235 4.14E-05 nitric-oxide synthase regulator activity HSP90AB1|HSP90AA1
43498 8.17E-05 cell surface binding TF|HSPD1|ANXA5
4859 2.71E-04 phospholipase inhibitor activity ANXA5|ANXA2
The proteins listed in the table are categorized by their bioprocesses and molecular functions -GO Analysis
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Fig. 3 Iron chelation decreased UW228 medulloblastoma sphere formation and growth. a Representative image of UW228 spheres at 5X and 10X
magnification in the presence of iron chelators in the culture medium (100 μM deferoxamine (DFO), 1 μM Dp44mT) or of iron (50 μM Ferric
ammonium citrate). b Number of spheres (counted using a light microscope) obtained in a T75 low adhesion plate after 72 h of culture in the
presence of different concentrations of DFO, Dp44mT or FAC (**p < 0.001). c Area of the spheres in arbitrary units (A.U) after 72 h of culture in the
presence of different concentrations of DFO, Dp44mT or FAC (*p < 0.05). d Limited dilutions assay in which 1 cell was plated in each low
adhesion culture 96 well-plate and after 14 days, the number of clonal tumor spheres formed in each well were counted in the presence of
100 μM deferoxamine (DFO), 1 μM Dp44mT or 50 μM of Ferric ammonium citrate (**p < 0.001)
Bisaro et al. Molecular and Cellular Therapies  (2015) 3:8 Page 9 of 12
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Bisaro et al. Molecular and Cellular Therapies  (2015) 3:8 Page 10 of 12
homeostasis (p = 10−3) and heme-related metabolic pro-
cesses (p = 10−5) in MB progression and invasion (Table 2).
The importance of iron for cells is related to the key role
of Fe-containing proteins involved in oxygen sensing, en-
ergy, metabolism, respiration, folate metabolism and DNA
synthesis (RR = ribonucleotide reductase). Without iron,
G1 – S progression is hampered for normal and tumoral
cells [29].
Iron has been recently described as an essential element
in tumor cell proliferation, supporting energy and structural
requirements of neoplastic cells. The role of iron in tumors
has been intensively studied in all phases of tumorigenesis,
and a specific influence of iron on tumor cell growth and
tumor progression has been revealed in many human can-
cers [30, 31]. Most studies on iron and cancer were per-
formed on epithelial or hematopoietic tumors and in vivo
experiments; a further difficulty is to distinguish between
the lowered iron concentration in tissues and organs and
the direct effect of chelation on tumor cells. Although DFO
and Dp44mT bind trivalent Fe, they have different actions.
DFO is a hexadentate chelator of Fe3+ with high affinity,
forming a 1:1 complex with iron and limited cell membrane
permeability. Dp44mT forms a complex with ferric iron in
a 2:1 ratio, with easy access into the cells. Furthermore,
Dp44mT forms redox-active iron and copper complexes
inside the cell, inducing the generation of ROS and relevant
cytotoxicity via a Fenton type chemical reaction (Fe2+
H2O2 – reactive intermediates – Fe
3+ + .OH+OH−) [32].
In vivo studies have demonstrated that Dp44mT and re-
lated molecules do not lower iron concentration in tissues
and biological fluids in the same way that DFO does. These
data are in line with a prominent intracellular accessibility
of Dp44mTcompared to Deferoxamine.
An interesting interpretation of the results may be the
fact that, although the main target of the compounds is iron
chelation, other ions (such as Cu, as well as non-metallic
ions) are bound by chelators.
In fact new iron chelators, such as Dp44mT, show
anti-tumoral activity unrelated to iron deprivation but
which interfere with relevant metabolic pathways [33].
More than half of human cancers express multidrug-
resistant P-glycoprotein (Pgp) and Pgp-dependent lyso-
somal damage and cytotoxicity has been demonstrated for
Dp44mT and related to Copper chelation. Several other
pathways, in different tumors, are targeted by these new
chelators, and the related anti-tumoral activity does not
involve Fe sequestration as a primary cause.
Our results obtained on iron chelation demonstrated that
only the permeable iron chelator Dp44mT is able to de-
crease sphere formation and stemness ability, highlighting a
crucial role of intracellular iron in supporting tumor
progression by EV communication. Moreover, the co-
presence of iron and Dp44mT in medullospheres re-
stored the number of spheres and cancer stem cells
control levels, emphasizing the role of iron in cancer
stem cell formation and enrichment.
Conclusions
In conclusion, our findings on MB cell lines modulating
iron-related proteins in different growth conditions are
of interest and create possible scenarios linking iron
metabolism to hypoxia, and could be potentially related
to increased cell proliferation, tumor aggressivity and
stemness. The influence of iron on the cellular division
rate has been studied in different tumors and has
opened the possibility to use chelators as adjuvants in
antitumoral chemotherapy.
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Fig. 4 Iron chelation decreased DAOY Medulloblastoma sphere formation and growth. a Representative image of DAOY spheres at 5X and 10X
magnification in the presence of iron chelators in the culture medium (100 μM deferoxamine (DFO), 1 μM Dp44mT) or of iron (50 μM Ferric
ammonium citrate) or 1 μM Dp44mT + 50 μM FAC. b Count by light microscopy of number of spheres obtained in a T75 low adhesion plate after
72 h of culture in the presence of 100 μM DFO, 1 μM Dp44mT, 50 μM FAC or 1 μM Dp44mT + 50 μM FAC (*p < 0.05). c Area of the spheres in
arbitrary units (A.U) obtained in a T75 low adhesion plate after 72 h of culture in the presence of 100 μM DFO, 1 μM Dp44mT, 50 μM FAC or
1 μM Dp44mT + 50 μM FAC (*p < 0.05). d Limited dilutions assay in which 1 cell was plated in each low adhesion culture 96 wells -plate and after
14 days, the number of clonal tumor spheres formed in each well were counted in the presence of 100 μM deferoxamine (DFO), 1 μM Dp44mT,
50 μM of Ferric ammonium citrate or 1 μM Dp44mT + 50 μM FAC (*p < 0.05)
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